These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 23591996

  • 1. Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma.
    Crooke A, Huete-Toral F, Martínez-Águila A, Martín-Gil A, Pintor J.
    J Pharmacol Exp Ther; 2013 Jul; 346(1):138-45. PubMed ID: 23591996
    [Abstract] [Full Text] [Related]

  • 2. Regulation of ocular adrenoceptor genes expression by 5-MCA-NAT: implications for glaucoma treatment.
    Crooke A, Huete-Toral F, Martínez-Águila A, Alarma-Estrany P, Pintor J.
    Pharmacogenet Genomics; 2011 Sep; 21(9):587-9. PubMed ID: 21705965
    [Abstract] [Full Text] [Related]

  • 3. Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT.
    Andrés-Guerrero V, Alarma-Estrany P, Molina-Martínez IT, Peral A, Herrero-Vanrell R, Pintor J.
    Exp Eye Res; 2009 Mar; 88(3):504-11. PubMed ID: 19056382
    [Abstract] [Full Text] [Related]

  • 4. Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5-MCA-NAT.
    Crooke A, Huete-Toral F, Martínez-Águila A, Martín-Gil A, Pintor J.
    J Pineal Res; 2012 Apr; 52(3):265-70. PubMed ID: 22107075
    [Abstract] [Full Text] [Related]

  • 5. Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice.
    Martínez-Águila A, Fonseca B, Pérez de Lara MJ, Pintor J.
    J Pharmacol Exp Ther; 2016 May; 357(2):293-9. PubMed ID: 26941171
    [Abstract] [Full Text] [Related]

  • 6. Melatonin receptors trigger cAMP production and inhibit chloride movements in nonpigmented ciliary epithelial cells.
    Huete-Toral F, Crooke A, Martínez-Águila A, Pintor J.
    J Pharmacol Exp Ther; 2015 Jan; 352(1):119-28. PubMed ID: 25344385
    [Abstract] [Full Text] [Related]

  • 7. Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits.
    Alarma-Estrany P, Guzman-Aranguez A, Huete F, Peral A, Plourde R, Pelaez T, Yerxa B, Pintor J.
    J Pharmacol Exp Ther; 2011 Jun; 337(3):703-9. PubMed ID: 21368006
    [Abstract] [Full Text] [Related]

  • 8. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor.
    Pintor J, Peláez T, Hoyle CH, Peral A.
    Br J Pharmacol; 2003 Mar; 138(5):831-6. PubMed ID: 12642384
    [Abstract] [Full Text] [Related]

  • 9. Requirement of intact sympathetic transmission for the ocular hypotensive effects of melatonin and 5-MCA-NAT.
    Alarma-Estrany P, Crooke A, Peral A, Pintor J.
    Auton Neurosci; 2007 Dec 30; 137(1-2):63-6. PubMed ID: 17804303
    [Abstract] [Full Text] [Related]

  • 10. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R, Queiroz CF, Santos LC, Avila MP, Magacho L.
    Clin Ther; 2006 Apr 30; 28(4):552-9. PubMed ID: 16750466
    [Abstract] [Full Text] [Related]

  • 11. The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analogue, 5-MCA-NAT, in rabbit eyes.
    Andrés-Guerrero V, Molina-Martínez IT, Peral A, de las Heras B, Pintor J, Herrero-Vanrell R.
    Invest Ophthalmol Vis Sci; 2011 Mar 18; 52(3):1507-15. PubMed ID: 21087964
    [Abstract] [Full Text] [Related]

  • 12. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
    Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S, Low-Pressure Glaucoma Study Group.
    Am J Ophthalmol; 2011 Apr 18; 151(4):671-81. PubMed ID: 21257146
    [Abstract] [Full Text] [Related]

  • 13. Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys. A species difference.
    Burke J, Kharlamb A, Shan T, Runde E, Padillo E, Manlapaz C, Wheeler L.
    Ann N Y Acad Sci; 1995 Jul 12; 763():78-95. PubMed ID: 7677389
    [Abstract] [Full Text] [Related]

  • 14. Changes in melatonin receptor expression in a murine model of glaucoma.
    Martínez-Águila A, Fonseca B, Pérez de Lara MJ, Miras-Portugal MT, Gómez-Villafuertes R, Carracedo G, Pintor J.
    Mol Vis; 2020 Jul 12; 26():530-539. PubMed ID: 32818016
    [Abstract] [Full Text] [Related]

  • 15. Sympathetic nervous system modulates the ocular hypotensive action of MT2-melatonin receptors in normotensive rabbits.
    Alarma-Estrany P, Crooke A, Mediero A, Peláez T, Pintor J.
    J Pineal Res; 2008 Nov 12; 45(4):468-75. PubMed ID: 18673419
    [Abstract] [Full Text] [Related]

  • 16. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension.
    WoldeMussie E, Ruiz G, Wijono M, Wheeler LA.
    Invest Ophthalmol Vis Sci; 2001 Nov 12; 42(12):2849-55. PubMed ID: 11687528
    [Abstract] [Full Text] [Related]

  • 17. Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes.
    Serle JB, Wang RF, Peterson WM, Plourde R, Yerxa BR.
    J Glaucoma; 2004 Oct 12; 13(5):385-8. PubMed ID: 15354076
    [Abstract] [Full Text] [Related]

  • 18. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.
    Prasanna G, Carreiro S, Anderson S, Gukasyan H, Sartnurak S, Younis H, Gale D, Xiang C, Wells P, Dinh D, Almaden C, Fortner J, Toris C, Niesman M, Lafontaine J, Krauss A.
    Exp Eye Res; 2011 Sep 12; 93(3):256-64. PubMed ID: 21376717
    [Abstract] [Full Text] [Related]

  • 19. Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency.
    Loma P, Guzman-Aranguez A, Perez de Lara MJ, Pintor J.
    Exp Eye Res; 2015 May 12; 134():141-7. PubMed ID: 25701803
    [Abstract] [Full Text] [Related]

  • 20. Contributions of adenosine receptor activation to the ocular actions of epinephrine.
    Crosson CE, Petrovich M.
    Invest Ophthalmol Vis Sci; 1999 Aug 12; 40(9):2054-61. PubMed ID: 10440261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.